Oncolytic viruses are a fast-developing cancer treatment field. Numerous viruses have been tested in clinical trials and three are approved. The first, Rigvir, is an immunomodulator with anti-tumour effect for treatment of melanoma, local treatment of skin and subcutaneous metastases of melanoma, for prevention of relapse and metastasis after radical surgery registered in Latvia, Georgia, Armenia and Uzbekistan. The aim of the present review is to summarize the development of Rigvir. Approximately 60 viruses were screened preclinically. Clinical safety and efficacy trials were with 5 oncolytic enteroviruses. Safety of the selected and melanomaadapted ECHO-7 virus Rigvir was tested in over 180 patients with no severe adverse events observed. Preregistration efficacy studies involved over 700 cancer patients: over 540 melanoma patients, and patients with late stage stomach (ca. 90), colorectal cancer (ca. 60), and other cancers. Patients were treated with Rigvir for 3 years after surgery and compared to immunotherapy: 3-and 5-year overall survival appeared to be increased in Rigvir treated patients. In post-marketing retrospective studies, Rigvir-treated stage II melanoma patients showed a 6.67-fold decreased risk for disease progression in comparison to those that had been observed according to guidelines, and stage IB and stage II melanoma patients that had received Rigvir therapy had 4.39-6.57-fold lower mortality. The results are confirmed and extended by case reports. Several immunological markers have been measured. In conclusion, Rigvir is an oncotropic and oncolytic virus for treatment of melanoma; the results will be confirmed and updated by modern clinical studies.
Introduction
Oncolytic virotherapy, which is a part of active immunotherapy, represents an intensely studied and rapidly developing niche in the cancer therapeutics field. Although clinical application of oncolytic virotherapy has just recently become widely available to cancer patients, observations of tumour regression after viral infections were made already in the 19th century (Bartlett et al., 2013; Kelly and Russell, 2007; Lichty et al., 2014; Liu et al., 2007; Mullen and Tanabe, 2002; Russell and Peng, 2018) . A woman with advanced breast cancer experienced a spontaneous tumour remission after a febrile disease (Dupuytren, 1829; Hoption Cann et al., 2006) . Until 1892 it was not known if infectious diseases are caused by virus or bacteria, nevertheless, there was hypothesised that some infectious diseases are of viral origin (Foster, 2002 ). An often cited clinical case of leukaemia that went into a temporal remission after a presumed influenza infection was also published quite early (Dock, 1904) .
Interest in virotherapy grew after a cervical cancer patient experienced a tumour regression following rabies vaccination. Soon, eight cervical cancer patients were inoculated with live-attenuated rabies virus vaccine (DePace, 1912; Power and Bell, 2007) . The results were encouraging since in some patients a temporary recovery with substantial tumour shrinkage was observed (Tayeb et al., 2015) . The first laboratory experiments of viral oncotropism and oncolysis were started. This led to the hypothesis that virus cellular tropism and replication is exclusively connected to the ability of the cell to support virus replication. Tumours were found to be more susceptible to viruses than normal cells, and that viruses preferentially replicate in tumour cells (Levaditi and Nicolau, 1922) . Several malignant tumour lines in mice and rats were successfully inhibited by injecting vaccinia virus (Southam, 1960) .
It was also noticed that it is possible to enhance (and reduce or lose) the oncolytic activity of a virus by multiple passaging in tumour tissue, and that adaptation of the virus to previously resistant tumours is achievable (Moore, 1952; Muceniece, 1972) .
These results promoted further research in the field of oncolytic virotherapy, and the first clinical trials involving cancer patients began in the 1940s. After a hepatitis B virus infection two patients with Hodgkin's lymphoma had gone into remission (Hoster et al., 1949) . Subsequently, 21 patients suffering from Hodgkin's disease were injected with hepatitis B virus infected sera and tissue. In 7 patients signs and symptoms disappeared, in 4 the tumour size decreased.
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Various viruses, such as West Nile virus and Newcastle disease virus were tested in clinical trials in a wide range of cancers (Moore, 1952) . It was shown that inhibition of tumour growth correlates with virus presence and multiplication in the tumour (Southam and Moore, 1952) . Further evidence of viral oncotropism and oncolysis was obtained in a clinical trial involving 34 advanced cancer patients unresponsive to any established treatment (Southam and Moore, 1952) .
In 1956, the first large-scale clinical trial of adenoidal-pharyngealconjunctival virus in late stage cervical carcinoma patients was initiated. In patients who responded, localized tumour destruction was prominent, but no significant tumour regression or remission was obtained, moreover survival was not significantly prolonged, and more than half of the patients died from cancer a few months after starting therapy (Carson et al., 2010; Kelly and Russell, 2007) .
The research shifted to the oncolytic potential of the mumps virus, which was tested in 90 patients with 18 different cancer types. Various virus delivery methods including oral, rectal, intratumor, inhalation and intravenous administration were tested. The results were promising and might be attributed to the oncolytic effect of the mumps virus. Tumours shrank in size or disappeared in 37 of 90 patients along with improvement in subjective symptoms. In addition, even after the remaining tumour was left untreated, 19 patients remained symptom-free for a substantial length of time (Asada, 1974) .
Genetic engineering progressed, resulting in easy DNA and RNA manipulation by the 1990ies, thus opening the door to viral genome altering and the generation of new oncolytic virus strains (Choi et al., 2016; Lin et al., 2018) . In genetical oncolytic virus engineering the main attention is drawn to creating viruses that selectively target tumour cells without harming healthy cells, particularly by decreasing virus pathogenicity and increasing viral oncotropic and oncolytic properties (Fukuhara et al., 2016) . The field of oncolytic virotherapy has grown tremendously. This has resulted in approximately 150 ongoing or completed oncolytic virotherapy clinical trials testing over 60 potential therapeutic oncolytic viruses (Pol et al., 2016; Russell et al., 2012; ta-Scan-Fact-sheet, 2017) . Several viruses with a great potential of becoming a treatment option for cancer are in development. One of these is pexastimogene devacirepvec (JX-594, Pexa-Vec) that entered Phase III clinical trial in patients with hepatocellular carcinoma in 2015 (Bommareddy et al., 2017; Cheng et al., 2015; Conry et al., 2018; Fukuhara et al., 2016; Garber, 2006) . Furthermore, several ongoing clinical trials are examining the synergy between oncolytic viruses and cytotoxic chemotherapy agents (Duffy et al., 2017) .
As of mid-2018, there are three oncolytic viruses registered. Rigvir and two genetically engineered oncolytic viruses, the adenovirus H101 (Oncorine) for squamous cell carcinoma of the head, neck and oesophagus in China (P.R.C.), and the genetically altered HSV-1 talimogene laherparepvec (Imlygic) for advanced melanoma treatment in the USA, Europe and Australia. This review, however, is focused on Rigvir.
Rigvir background information
The first oncolytic virus registered and approved is Rigvir. It was first registered in Latvia in 2004 (Doniņa et al., 2015; Hastie et al., 2016) . Rigvir as an immunomodulator with anti-tumour effect is approved and registered for treatment of melanoma, local treatment of skin and subcutaneous metastases of melanoma, for prevention of relapse and metastasis after radical surgery in Latvia, Georgia, Armenia and Uzbekistan. Rigvir is an oncolytic virus belonging to the Picornaviridae family, Enterovirus genus, ECHO group, type 7, that has not been genetically modified but has been selected and adapted for melanoma. ECHO is an abbreviation for Enteric Cytopathogenic Human Orphan, since the host for ECHO viruses is man (Fig. 1) .
The prototype ECHO-7 virus is the Wallace strain. While the nucleotide sequence of Rigvir is similar to that of the Wallace strain, it is not identical. The amino acid sequence identity of Rigvir and 5 other ECHO-7 virus isolates, including Wallace, is reported to be highly conserved, 95.31-99.73% (Hietanen et al., 2018) .
Rigvir is supplied as a solution for intramuscular injection at a titre of not less than 10 6 TCID 50 /mL in sodium chloride for injection. It should be stored at − 20 ± 2°C and transported frozen. Rigvir is reimbursable for Latvian melanoma patients since 2011 and is included in the national guidelines for skin melanoma since 2015. According to data from the National Health Service of Latvia (July 2011-May 2018) over 2/3 of the reimbursed melanoma patients (ICD-10 C43.0-C43.9) have been treated with Rigvir.
The development of Rigvir can be traced back to the late 1950's. It was developed in laboratories and clinics in Riga, Latvia.
During the 1950's, major breakthroughs in the development of polio vaccines were achieved (Sabin, 1981; Salk and Salk, 1977) . In Riga the inactivated Salk vaccine was in clinical use from June 1957 (Kukaine, 1962; Muceniece and Ferdats, 1985) . Tests with the live, attenuated Sabin vaccine started in Latvia in 1959 (Kukaine, 1962; Muceniece and Ferdats, 1985) . The Latvian virologist team isolated several viruses from the gastrointestinal tract of healthy children to monitor the effect of the polio vaccine on the natural virus flora. For virus isolation human embryo fibroblast cultures and monkey kidney tissues were used. Overall, 182 virus strains were isolated form the faeces of 303 children (Volrāte, 1960 (Volrāte, , 1962 . Some of the enteroviruses had oncolytic properties and were exclusively oncotropic in various human tumours grown in short term tissue cultures or as heterotransplants. Furthermore, Dr. Muceniece et al. observed that following repeated passages of virus on human tumours, the oncotropic and oncolytic properties of the virus can be substantially increased. This resulted in the adaptation of an ECHO-7 virus strain to melanoma (Brūvere et al., 2002b; Muceniece, 1972 Muceniece, , 1988 .
The results of the Rigvir development were reported as prudent summaries, mainly in Latvian and Russian. Only rarely, and mostly due to personal encounters, were these studies described across the Iron Curtain in contemporary Western scientific literature, cf. (Austin and Boone, 1979; Chernobayeva and Muceniece, 1966; Ozoliņš, 1995) .
Rigvir preclinical studies

Screening of oncolytic viruses
By the time the polio vaccine (sub-)project was finalized the Latvian team was ready for new challenges. The team now had experience of working on a large and successful project and, although indirectly, they had also participated in an international project. Another legacy was a freezer full of isolated virus strains from unvaccinated healthy children. These viruses were made good use of. They formed the backbone of the virus panel that also included viruses from the Sabin laboratory collection, which was screened in cancer models (Muceniece, 2005) .
Dr. Aina Muceniece decided to test the oncolytic properties of the collected viruses. Approximately 60 different types of viruses were screened, including ECHO 1-19, Coxsackie A1-A19, B1-B5, and a few pathogenic polioviruses, in heterotransplants of human angiosarcoma, chondrosarcoma and lymphosarcoma in the cheek pouch of Syrian hamsters (Aleksandrova et al., 1969; Garklāva and Muceniece, 1966; Muceniece and Chernobayeva, 1963) (Fig. 2) . The virus was injected intramuscularly and after 4 days the animals were killed, and the tumours were examined microscopically. The results suggest that most of the tested ECHO viruses showed tropism for tumours in heterotransplants. Only Coxsackie A4, B3 and B5, however, showed oncotropic features when tested in chondrosarcoma and rat sarcoma (Muceniece and Chernobayeva, 1963) .
Virus adsorption of 2, 4, 6, 7, 11, 12, 15, 16 and Coxsackie A-3 and A-15 to tumour models (human angiosarcoma heterotransplants in hamsters, rat sarcoma M-1 and rat reticulosarcoma) was tested with a fluorescence method. Imprints of tumour samples infected with viruses were made and stained with fluorescent antibodies. The results showed that viruses have different adsorption time. Adsorption to 50% of the cells was observed after 15 min for ECHO-7 and ECHO-4, and after 60 min for ECHO-6 and ECHO-11 (Aleksandrova and Garklāva, 1969) .
This method was also used to investigate adsorption of ECHO-1, 4, 6, 7, 11, 15 and 16 viruses in human surgical tumour samples (stomach, breast, female genital tract cancer, sarcoma). Different tumours were tested in vitro and the highest adsorption was observed for ECHO-7, 4, 11 and 16 viruses (Aleksandrova et al., 1969) .
The viruses were further tested in tissue cultures and heterotransplants of human angiosarcoma in hamsters; 31 of 48 ECHO and Coxsackie viruses replicated in heterotransplants, and in the angiosarcoma tissue culture a cytopathic effect was observed for 11 of 48 the viruses. ECHO-7 showed tropism for angiosarcoma in heterotransplants, but in angiosarcoma tissue culture no cytopathic effect was observed (Garklāva and Muceniece, 1966) .
The adsorption of ECHO-4, 6, 11, 15, Coxsackie A-3 and three varieties of ECHO-7 virus (ECHO-7, ECHO-7/16, ECHO-7/17) to ten samples each of human breast and stomach cancer tissue was also tested. ECHO-7 and ECHO-11 viruses were adsorbed to 66% and ECHO-6 was adsorbed to 50% of the breast cancer samples. The other ECHO viruses were adsorbed to a lesser extent (ECHO-15 in 37%, ECHO-7/16 and ECHO-7/17 in 33% and ECHO-4 in 20%). In the stomach cancer, ECHO-6 virus was adsorbed to 75% of the samples, ECHO-7/17 to 66%, ECHO-4 to 55%, ECHO-11 to 50%, ECHO-7 to 43.5%, and ECHO-15 to 37%. ECHO-7/16 was adsorbed only in one of 6 tumours. This experiment was further extended to test if a correlation can be found between ECHO virus adsorption and the presence of antibodies against ECHO viruses in the circulation. Adsorption of ECHO viruses was observed also in those tumour samples that were obtained from patients having antibodies against ECHO viruses, suggesting that ECHO antibodies might not influence virus adsorption (Garklāva, 1969) .
Morphological changes of human osteosarcoma cells after infection with ECHO-7 virus have been described. Changes in cell morphological structure was observed at 30 min and 1, 3, 6, 12 and 24 h. Increase in disturbed mitotic activity was observed during all time points; the authors suggested that disruption of mitotic activity can be considered the cytopathic effect (Grigalinovičs and Petrovska, 1988) .
Recently, the effect of Rigvir on cell viability has been tested in several cell lines of human origin by live cell imaging. The viability was decreased in FM-9, RD, AGS, A549, HDFa, HPAF II and MSC cell cultures by 67-100% and in HaCaT cell culture by 46%. PBMC, MCF7 and Sk-Mel-28 cell count was not affected. The presence of ECHO-7 virus in the cells was detected by ECHO-7 antibodies in FM-9, RD, AGS, A549, HDFa, HPAF-II and Sk-Mel-28 cells. The presence of ECHO-7 in the cells preceded and / or coincided with the time of reduction of cell viability. The observed effect of Rigvir on cell viability was dose-and time-dependent (Tilgase et al., 2018b) .
Pre-clinical immunomodulatory effects
Several pre-clinical immunomodulatory effects of Rigvir have been observed. For example, in mouse tumour models Rigvir induced formation of lymphoblasts and plasmoblasts in regional lymph nodes, Tlymphocytes, albumin, post-albumin and slow posttransferins, caused the formation of large clusters of lymphocytes and plasmocytes around the edges of the tumour and within tumours, especially around the vessels, and decreased the mass of local lymph nodes (Aina Muceniece, 1987, unpublished) .
Preclinical in vivo efficacy models
Rigvir has been tested in several rodent in vivo models, assuming that while Rigvir does not infect the animal, it will influence its immune system. Thus, Rigvir has been tested in rat sarcoma M-1 and KRS-321, mouse Moloney virus-induced sarcoma, and mouse MH-17 chemicallyinduced tumour models (Aina Muceniece, 1987, unpublished) .
Following three administrations with an interval of 3 days the volume of 11 of 20 tumours regressed after 28 days in the rat M-1 sarcoma model and in 11 of 25 in the rat KRS-321 model. In the Moloney virusinduced mouse sarcoma the number of lymphocytes was 3-4 larger than in control. In mice with MH-17 the tumour mass induced by methylcholanthrene was reduced by Rigvir by approximately 30% compared to control.
Mechanism of infection
The host for ECHO-7 virus is man. For infection ECHO-7 virus has been suggested to use CD55 (Bergelson et al., 1994; Clarkson et al., 1995; He et al., 2002; Plevka et al., 2010; Spiller et al., 2000; Ward et al., 1994) , CD59 , and β2-microglobulin (Ward et al., 1998) receptors to enter cells. There does not seem to be any evidence that CD54 is used by ECHO-7 virus . CD55 (or decay-accelerating factor, DAF), is a cell surface glycoprotein, which regulates complement activity by accelerating the decay of C3/C5 convertases. The specificities of these receptors are an important determinant of viral host range and tissue tropism. 
Rigvir clinical studies
Clinical markers
Since Rigvir is an immunomodulator, potential immunological markers have been determined in peripheral blood in several studies. It is known that the immune system has a distinct role in oncogenesis. It can either suppress the tumour development or even boost tumour growth (Schreiber et al., 2011) . Most of the results characterize the humoral and cellular immunity response to Rigvir of skin melanoma patients compared with healthy volunteers.
A commonly observed side effect for oncolytic viruses, including Rigvir, is sub-febrile temperature, suggesting an immunomodulating effect (Nalin, 2006) . One of the markers analysed is T-lymphocytes measured using the spontaneous E-rosette forming method with sheep or mice erythrocytes, often used in the 1970's -1990's. The rosettes consist of lymphocytes encircled by a group of attached sheep erythrocytes and are used for determining T-lymphocytes and their participation in different pathological states. With this method the total count of T-lymphocytes and active T-lymphocytes was detected (Boldt and Armstrong, 1976) .
Several studies of the humoral and cellular immunity were performed in skin melanoma patients, benign neoplasm patients and healthy volunteers. For humoral immunity testing, Rigvir was administered in 78 skin melanoma patients and 18 healthy volunteers, resulting in an increase of B-lymphocytes in all skin melanoma patients 24-48 h after the first Rigvir administration (Glinkina et al., 1992b) . 93 skin melanoma patients, 6 patients with benign skin neoplasm and 18 healthy volunteers were administered Rigvir to test the cellular immunity. Comparison of skin melanoma patients treated with Rigvir with those who were not, showed that the number of immunocompetent cells did not decrease in patients after surgery who received Rigvir before surgery as opposed to the latter. Increase of active T-lymphocytes was observed in 92% healthy volunteers and 50% skin melanoma patients and increase of theophylline resistant T-lymphocytes in 91% healthy volunteers and 55% skin melanoma patients. Therefore, Rigvir administration before surgery stabilised the humoral immunity after surgery. Theophylline resistant T cells are known to preserve the E rosette forming ability after the exposure to theophylline and express helper activity (Limatibul et al., 1978; Shore et al., 1978) .
In a study involving gastric cancer patients an increase up to 20% of T-lymphocytes in the tumour and mucous was observed after Rigvir administration before surgery in early stage gastric cancer patients (Glinkina and Brūvere, 1992) . When Rigvir was administered in 20 healthy volunteers an increase of immunoglobulin M levels from 1.65 to 3.35 g/l was detected a month after the administration (Ferdats et al., 1993) .
After Rigvir administration to healthy volunteers the levels of CD4 + , CD8 + and CD38 + lymphocytes determined after 24-48 h were not altered (Glinkina et al., 1992a) . In melanoma patients, the CD4 + levels were not altered after 24-48 h, and the CD8 + and CD38 + were decreased by 10-15% (Glinkina et al., 1992a) . In another report Rigvir was administered to 42 skin melanoma patients and 18 healthy volunteers. The most notable change was observed in active T-lymphocyte levels. In the healthy volunteers active Tlymphocyte count increased by 61%. In patients that received Rigvir preoperatively active T-lymphocyte count was increased by 59%. An increase in theophylline resistant T-lymphocytes by 29% and a decrease in CD38
+ by 35-52% was also detected at 24-48 h after Rigvir administration. Immunocompetent cells were measured again 12 months after the first Rigvir administration. In melanoma patients an increase in active T-lymphocyte count by 16-86% and theophylline resistant Tlymphocyte count by 2-51% were still detected (Glinkina, 1993) . Tests were made to determine if the melanoma associated antigen (MAGE) could be a molecular marker of malignant melanoma progression. The antigenic profile of melanoma tissues with different degree of disease was assessed and compared to tumour thickness, level of invasion, cell type growth and ulceration. The expression of MAGE-1, tyrosinase, MART and gp100 antigens were also observed; 7 non-malignant tissue samples (nevi, keratoma) and 55 biopsy samples (48 primary skin melanoma samples and 7 metastatic melanoma samples) were used. The results showed that antigen expression encoded by MAGE genes and histological features paralleled with tumour progression (86.2% of samples were melanoma associated antigen positive for ulceration and 75.5% for tumour thickness more than 4.0 mm by Breslow). One year later, 31 melanoma patients were examined and tested for MAGE expression (13 patients with progression metastatic disease or relapse and 18 progression-free patients). 11 of the 13 patients with progression were MAGE positive, whereas only 5 of the 18 patients of the progression-free group were MAGE positive (Heisele et al., 2000) . These findings were confirmed in tests made to detect MAGE mRNA using 62 melanoma samples and 12 samples from patients after Rigvir therapy (Heisele et al., 2001) . It was concluded that the correlation with disease progression makes MAGE a possible prognostic marker. In a preliminary study 60% (6 of 10 patients) of melanoma tissue specimens were MAGE positive, 56% (35 of 62) after surgery were positive, while only 17% (2 of 12) Rigvir treated were MAGE positive (Brūvere et al., 2002a) .
It has been suggested that Rigvir induces increases of lymphocyte subpopulations from cancer patients such as CD3 + , CD8 + , CD38 + and CD95 + (Brūvere et al., 2002a) .
By 72 h after Rigvir administration CD8+ levels increased to 49% above the highest reference range, CD38
+ cells increased to 31%, and CD95 + to 241% above the upper level of the reference range. While CD3 + levels were within the reference range 72 h after Rigvir administration, by 3 weeks the CD3 + levels had increased to 15% above the highest level of the reference range and CD8 + to 33% above the highest reference range. In contrast, after 3 weeks the CD38 + and CD95 + levels were 61% and 72% below the lowest level of the reference range, respectively (Brūvere et al., 2002a) . The CD4 + levels were within the reference range both after 72 h and after 3 weeks. The CD16 + levels were within the reference range after 72 h and decreased to 81% below the lowest level of the reference range after 3 weeks. The HLA-DR levels decreased at both time points to 62% and 88% below the lowest level of the reference range, respectively (Brūvere et al., 2002a) . In a recent retrospective study, haematology parameters were analysed in 76 cancer patients before (Day 1) and a day after three daily administrations of Rigvir (Day 5). The largest patient groups were breast cancer, melanoma, colorectal cancer, and prostate cancer patients comprising 64.5% of the patients. IgA was significantly increased with a median change of 6%, IgG was significantly increased with a median change of 2%, and CD19 was found to be significantly decreased with a median decrease of 10%. There was no significant change in CD3 Taken together, the measured changes in immunological parameters appear to be minute and variable and could not be analysed between treatment groups. Since these cells are widely recognised as immunological markers, the effect of Rigvir on immunological parameters might be investigated further.
Rigvir clinical experience 4.2.1. Clinical studies: when, what, and where
The first clinical trial of what was to become Rigvir was approved on 25 April 1968 by the local competent authority. Studies were conducted according to the standards prevailing in Latvia at the time. The major part of the Rigvir pre-registration clinical studies was performed during the period from 1968 to 1991. All patients were treated with Rigvir, the studies were not randomised and double-blind, and the control groups were comprised of historical controls. The first-in-man study was a safety study in late stage patients with various cancers that had been unsuccessfully treated with traditional methods, surgery, radiotherapy and/or chemotherapy. The safety and efficacy of 5 different oncolytic enteroviruses, ECHO-4, ECHO-6, ECHO-7, ECHO-11, and ECHO-16, were tested in parallel at two sites in Riga, the Pauls Stradiņš Clinical University Hospital and the Oncology Dispensary.
For further development, the ECHO-7 virus was subsequently selected and adapted to melanoma. The drug candidate has interchangeably been referred to as a viral immunomodulator, viral-nature immunomodulator with anti-tumour properties, or 'Rivir', until the name Rigvir was officially approved in 1989.
The subsequent studies were performed at the Pauls Stradiņš Clinical University Hospital, the Latvian Oncology Centre of Riga Eastern Clinical University Hospital (the successor of the Oncology Dispensary), and the Faculty of Dentistry of the Riga Stradiņš University. The clinical studies were first conducted in Riga and later multicentre and multinational studies outside Latvia were initiated. The studies continued approximately until 1991 when a period of political change that significantly influenced the development of Rigvir led to the regained independence for Latvia.
Rigvir mode of administration
The mode of administration in the clinical studies described, and consequently the approved mode, is intramuscular, with start of treatment not earlier than 2-3 weeks after surgery or when the wound has healed, if not otherwise stated. Typically, a dose was 2-20 × 10 6 TCID 50 per administration for three consecutive days with 3-4-week intervals during the first 3 months. Subsequently, administration is once a month during the first year, every 6 weeks during the first half of the second year, and every two months from the second half of the second year. Thus, administrations are made less frequently and with increasing intervals and usually for 3 years; however, nothing limiting the duration of the treatment has been found.
Rigvir clinical safety
The safety of Rigvir was tested in clinical trials before approval and registration of the marketing authorization. More than 180 stage III and (predominantly) stage IV melanoma, stomach, lung, sarcoma, and colorectal cancer patients were involved in the Rigvir safety studies (Januškevičs et al., 1988; Muceniece, 2005; Priedīte et al., 1971) . The most commonly observed side effects were sub-febrile temperature, pain in the tumour area, fatigue, sleepiness, and dyspepsia. The side effects were few, reversible, lasted for a couple of days and did not require treatment. The patients were not pre-medicated with analgesics or antipyretics. There is no record of discontinuation of Rigvir treatment due to side effects. The safety profile for Rigvir is remarkable since often the acceptance of side effects correlates with the severity of the disease treated.
The safety findings have been confirmed and extended in postmarketing studies. None of the post-marketing studies have found any record of significant adverse events from Rigvir treatment or its discontinuation. The first was a retrospective study in 80 patients, 44 of which had been treated with Rigvir: no adverse events had been recorded (Doniņa et al., 2012) . In the more recent retrospective study of 79 patients, 52 of which had been treated with Rigvir, safety assessment of serum clinical chemistry parameters was graded according to NCI CTCAE and did not show any value above Grade 2 in the Rigvir treated patients (Doniņa et al., 2015) . For the 27 patients that were observed there were 1447 analyses of clinical serum chemistry parameters made. Of those parameters 45 were Grade I, 2 Grade II, and 5 Grade III. For the 52 Rigvir treated patients there were 1607 analyses made. Of those parameters there were 18 Grade I, 5 Grade II, and none Grade III (Doniņa et al., 2015) .
In the case report studies safety assessment of serum clinical chemistry parameter values higher than Grade 1 according to NCI CTCAE have not been observed during Rigvir treatment (Alberts et al., 2016; Ismailov et al., 2018; Proboka et al., 2018; Tilgase et al., 2018a) .
Generally, for the class of oncolytic viruses the selectivity for cancer cells vs. healthy cells is quite high, 100-10000-fold (Fiola et al., 2006; Lam et al., 2011; Parato et al., 2012) . In the case of viruses, the inherent pathogenicity is determined. It has been reported that perhaps a little less than half of non-polio enterovirus infections might be asymptomatic; however, the more carefully the clinical symptoms are examined, the lower is the reported number of asymptomatic infections (Cherry, 2004; Cherry and Krogstad, 2014) . Interestingly, these authors also state that all too frequently isolation of enteroviruses "from stool is equated with assumptions of infection. This assumption is an error because illness, if it takes place, occurs shortly after the acquisition of virus and is short-lived; a particular infection may have been associated with a nonspecific illness 2 or 3 months before a stool specimen is obtained", and forgotten (Cherry, 2004; Cherry and Krogstad, 2014) . Moreover, in several clinical studies where illness manifestation could have been documented, "clinical observations apparently were of secondary importance" (Cherry, 2004; Cherry and Krogstad, 2014 ) (for example, febrile illness was an exclusion criterion of the study of (Gelfand et al., 1963) ). At least 49% of Coxsackie and 55% of ECHO virus infections appear to be subclinical; after correction for expected illness (adjustment for age, season, and pre-and post-infection experience of the infected persons), the calculated values for subclinical infection were 76-81% for coxsackie and 81-91% for ECHO viruses (Kogon et al., 1969) . The latter estimates have directly or indirectly been interpreted in recent reviews as a "majority" (Romero, 2007) , as more "than 90% of infections caused by the non-polio enteroviruses are asymptomatic or result only in undifferentiated febrile illness" (Romero and Modlin, 2015; Schwartz, 2018) or that "more than 90% of echoviral infections are asymptomatic" (Choudhary, 2017) . However, nonspecific fever is in fact the most common symptom and lasts only for about 3 days (Cherry, 2004; Cherry and Krogstad, 2014) . Importantly, ECHO viruses have not been shown to have any deleterious effect during pregnancy (Ornoy and Tenenbaum, 2006) . 4.2.4. Rigvir clinical efficacy 4.2.4.1. Rigvir pre-registration studies. More than 700 patients that had been diagnosed with melanoma (over 540, mainly stage I-III and about 40 stage IV, patients), late stage colorectal cancer (ca. 60), cancer of the stomach (ca. 90), as well as other cancers such as kidney, urinary bladder, pancreas, breast, lung, ovary, uterus, and sarcomas participated in the pre-registration efficacy studies (Alberts et al., 2016; Brūvere et al., 2002a; Doniņa et al., 2015; Muceniece, 2005) . During the efficacy studies all stages (I-IV) of melanoma patients were treated with Rigvir for 3 years after surgery, and 3-and 5-year overall survival was determined. The control group was accordingly treated with immunotherapy (for example, Corynebacterium parvum, splenin, zymosan, levamisole (decaris)) (Brūvere et al., 2002a; . The overall survival percentages appeared to be increased for the Rigvir treated patients. The studies have only been published as preliminary summaries of the results (Brūvere et al., 2002a; Čēma et al., 2001; Ferdats et al., 1999; Glinkina, 1993; Glinkina and Brūvere, 1992; Muceniece et al., 1989b; Rudzītis et al., 1988) .
In melanoma patients the 3-and 5-year survival, for control patients overall survival was 54-57% and 42-56%, and for Rigvir patients it was78-84% and 66-81%, respectively (Brūvere et al., 2006 (Brūvere et al., , 2002a Muceniece et al., 1989a) .
Rigvir has also been tested in gastric and rectal cancer patients, where 5-year survival also appeared to be improved (Brūvere et al., 2002a (Brūvere et al., , 1980 Garklāva et al., 1981 Garklāva et al., , 1979 .
For stage III stomach cancer patients that had been treated with Rigvir the 5-year survival post-surgery was 47-60%, compared with 24-33% for those that had not been treated with Rigvir. Furthermore, for stage II-IV rectum cancer patients the 5-year survival post-surgery was 41-68%, compared with 71-78% for those that had also been treated with Rigvir (Alberts et al., 2016; Brūvere et al., 2002a; Doniņa et al., 2015) .
An example of the histology studies is shown in Fig. 3 . In a stage IV melanoma patient subcutaneous metastases after Rigvir treatment were observed. The subcutaneous metastases were seen to be absorbed after several administrations of Rigvir (Muceniece and Venskus, 2007b) . Furthermore, the immunomodulating effect of Rigvir therapy has been visualised with lymphocytes surrounding a melanoma cell (Fig. 4). 4.2.4.2. Rigvir post-marketing experience. In general, patients are treated according to national and international guidelines. For melanoma patients, guidelines suggest a multitude of treatments for stage III and stage IV patients. In contrast, the guidelines suggest little, if anything, post-surgery for early stage melanoma patients. For example, the 2010 British Association of Dermatologists guidelines for the management of cutaneous melanoma state that "there is no evidence of a survival benefit for adjuvant chemotherapy in patients with melanoma" and "interferon is not recommended as standard of care for adjuvant therapy of primary or stage III melanoma" since the effect on diseasefree survival is of "uncertain clinical relevance"; instead, patients should be offered to participate in adjuvant clinical trials (Marsden et al., 2010) . The 2018 US NCCN melanoma guidelines post-surgery suggest only observation for substage IB and IIA patients, and for substages IIB and IIC observation or interferon alpha, in a footnote commenting that adjuvant interferon has been shown to improve disease-free survival "but there is no impact on overall survival" (NCCN, 2018) . The EDT/EADO/EORTC guidelines suggest treatment starting with stage II but note that there was no significant benefit in terms of overall survival (Garbe et al., 2016) . The ESMO and the NICE guidelines suggest adjuvant treatment post-surgery only starting with stage III melanoma (Dummer et al., 2015; NICE, 2015) . In this context it should be noted that when the international guidelines do not suggest any treatment for a specific melanoma stage, this does not mean that therapy is not needed or recommended but that there is no medicine approved and available for this patient category. Consequently, most of the melanoma patients that are treated with Rigvir are early stage (I-II) melanoma patients post-surgery.
The first Rigvir post-marketing study compared the progression-free survival post-surgery in melanoma patients (Doniņa et al., 2012) . For this retrospective registry study 298 patient records were available; after surgery 116 patients had been treated with Rigvir, 97 had been observed (according to guidelines), and 85 had received other treatments. The target population for the study was stage II melanoma patients that had been treated with Rigvir from 1 January 2008 and were analysed as of 1 February 2012. Excluded were patients that had a shorter follow-up period than 1 month, had received other treatment(s), and were stage I, III and IV patients. In this study 44 Rigvir treated stage II melanoma patients were included, and 36 patients that had only been observed according to current international melanoma guidelines. Age and sex was not statistically significantly different between the groups (P > 0.05) (calculated from the data of Doniņa et al. (2012) ).
The progression-free survival was analysed by Kaplan-Meier analysis (Fig. 5) . The results show that the risk for disease progression (calculated as hazard ratio) was statistically significantly (P < 0.001) decreased 6.67-fold by Rigvir treatment compared to observation (Doniņa et al., 2012) .
In the second post-marketing retrospective study the effect of Rigvir compared to observation was analysed on both the time to progression and overall survival (Doniņa et al., 2015) . Patients treated with interferon were excluded since they were too few to allow for a comparison. Caucasian melanoma sub-stage IB, IIA, IIB, and IIC patients who had undergone surgical excision of melanoma and whose diagnosis was verified between January 2008 and December 2011 were included in this study. All patients were free of disease after surgery; 52 patients had been treated with Rigvir, and 27 had been observed according to current international guidelines. The patients had been followed for at least 3 months and the follow-up period was not statistically different between both groups. Cox proportional hazards survival regression analysis was used since this is the most commonly used multivariate model in survival analysis. Any differences between the groups for example in age were taken into account in the Cox analysis.
Although the Rigvir treated patients appeared to be disease-free for a longer period, the difference was not statistically significant. This could have been due to slightly lower precision in the dates of progression for the observed patients since they did not need to obtain prescriptions and likely did not have as frequent visits.
The Rigvir treated patients showed a significant improvement in overall survival and had 4.39-6.57-fold lower mortality calculated as the hazard ratio (Fig. 6) (Doniņa et al., 2015) . This difference is both statistically and clinically significant.
It was concluded that Rigvir significantly prolongs survival in early stage melanoma patients without any serious side effect.
Taken together, these two post-marketing studies suggest that a 6-fold increase by Rigvir in progression-free survival predicts an effect of a similar magnitude on the overall survival in stage II melanoma patients.
Recent retrospective case reports confirm and extend the previous results. These patients had been diagnosed with stage IV histiocytic sarcoma, stage III small-cell lung cancer, stage IV M1c melanoma (Alberts et al., 2016) , melanoma unknown primary with brain metastasis (intramuscular and intranasal administration) (Proboka et al., 2018) , stage IV colorectal cancer (Tilgase et al., 2018a) , and stage IV chromophobe renal cell carcinoma (Ismailov et al., 2018) . The patients have received virotherapy with Rigvir for several years. The degree of regression of the disease was determined by computed tomography (CT) and contrast-enhanced head and brain magnetic resonance imaging (MRI) scan. The diagnoses of the patients were verified by histology or cytology. All patients started Rigvir treatment within a few months after being diagnosed.
For histiocytic sarcoma, which is an orphan disease with no standard therapy, the expected 5-year survival of 45% is based on only 9 patients (Gounder et al., 2015) . The patient did not have any surgery but had been prescribed symptomatic treatment, apparently since histiocytic sarcoma has been characterized by aggressive progression with little response to therapy (Abidi et al., 2007; Gounder et al., 2015; Grogan et al., 2008) . After 2 years of Rigvir treatment the patient was referred to the Oncological Centre once again for a medical examination. There the patient was treated with radio-and chemotherapy with good results on lymph node diameter, suggesting an additive effect with virotherapy. Interestingly, it has recently been indicated in a single arm phase 1b study with 21 advanced melanoma patients that combination treatment with another oncolytic virus has additive effect to an anti-PD-1 antibody (Ribas et al., 2017) ; there are several combination studies with oncolytic viruses on-going, see for example Pandha et al., 2017; Russell and Peng, 2017) .
The expected survival for cases with these diagnoses, if treated with standard treatments in the USA, for melanoma stage IV M1c can be estimated to 8-22% (Edge et al., 2010) , for small-cell lung cancer stage III less than 8% (Greene et al., 2002) , for melanoma brain metastasis the median survival is less than a year and the estimated 5-year survival is less than 10% (Sandru et al., 2014) , and for stage IV chromophobe renal cell carcinoma stage the estimated 2-year survival is less than 20% (Edge et al., 2010) .
The patients undergoing Rigvir treatment were diagnosed 6.6, 7.0, 3.5, 3.8, 7.5, and 2.4 years before publication, which by 3 August 2018 corresponds to 8.8, 9.2, 5.6, 4.3, 7.8 and 2.6 years since diagnosis, respectively, and their condition has improved and remains stable.
These results are promising and suggest that Rigvir clinical trials . Statistical difference between groups: P < 0.001 (from Doniņa et al. (2012) , with permission). Fig. 6 . Cox regression analysis plots of the effect of Rigvir on overall survival of melanoma patients following surgery. P is the statistical significance of the difference between the Rigvir (-) group and the observation according to current guidelines (observation) group (---) after adjustment for age, sex and sub-stage; hazard ratio (HR), 95% confidence interval (CI) (from Doniņa et al. (2015) , with permission). A. Substages IB, IIA, IIB, IIC, Rigvir® (N = 52), observation (N = 27), P < 0.005, HR = 6.27 (CI: 1.75-22.43). B. Substages II (A, B, C), Rigvir® (N = 35), observation (N = 22), P < 0.032, HR = 4.39 (CI: 1.14-16.98). C. Substages IIB and IIC, Rigvir® (N = 19), observation (N = 17), P < 0.014, HR = 6.57 (CI: 1.47-29.46). would be indicated in melanoma as well as sarcoma, small-cell lung cancer, colorectal cancer and renal cell carcinoma.
Current Rigvir development
Since the major part of the Rigvir pre-registration clinical studies were performed in the time from1968 to1991, modern studies are planned. They include both preclinical and clinical studies that will confirm and extend the Rigvir knowledge base on safety and efficacy. The planned clinical studies also intend to identify markers and widen the range of indications. A recent trend in oncology is combination therapy, thus adding a potential treatment model to test Rigvir with, for example, an anti-PD-1 antibody. To document the safety, a GCP registry will be started shortly.
Conclusions
The present results suggest that Rigvir is the first oncolytic virotherapy that is approved for treatment of melanoma. It has been used also in several other cancers, for example, gastric and rectal cancer. Rigvir is a genetically non-modified, oncotropic and oncolytic ECHO-7 virus; the side effects are low grade and well tolerated. The first Rigvir marketing authorization was approved in 2004 and Rigvir has been reimbursed in Latvia since the middle of 2011, where over 2/3 of the reimbursed melanoma patients have been treated with Rigvir. Since most of the clinical studies were performed before 1991, the results would benefit from updated, modern safety and efficacy clinical studies. As a part of this, also appropriate biomarkers are being sought to more accurately identify the right target patient population to increase the response rate. Rigvir is a promising immunotherapy medicine for the treatment of melanoma and prevention of metastases as a monotherapy, and potentially also in other cancers as well as in combination therapy.
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